Document:

Co-Promotion Agreement

 EXHIBIT 10.2 
 [***] Certain information in this document has been omitted and filed separately with the Securities and Exchange Commission. Confidential treatment has been requested with respect to the omitted
portions. 
 CO-PROMOTION AGREEMENT 
 This Co-Promotion Agreement (this “Agreement”) is made and entered into effective as of January 28, 2011, by and between MAP Pharmaceuticals, Inc., a Delaware corporation
having an address at 2400 Bayshore Parkway, Suite 200, Mountain View, California 94043 (“MAP”), and ALLERGAN USA, Inc., a Delaware corporation having an address at 2525 Dupont Drive, Irvine, California 92612
(“ALLERGAN”). MAP and ALLERGAN are sometimes referred to herein individually as a “Party” and collectively as the “Parties.” 
 RECITALS 
 WHEREAS, ALLERGAN and MAP have entered into a Collaboration
Agreement dated January 28, 2011 (the “Collaboration Agreement”); 
 WHEREAS, the Collaboration Agreement
grants ALLERGAN certain co-exclusive rights to Commercialize Product to Physician Targets for use in the Field in the Territory; and 
 WHEREAS, the Parties desire for MAP and ALLERGAN to Commercialize Product to Physician Targets for use in the Field in the Co-Promotion Territory pursuant to the terms and conditions of this Agreement and
the Collaboration Agreement. 
 NOW, THEREFORE, in consideration of the foregoing promises and the mutual representations,
warranties, covenants and agreements contained herein and in the Collaboration Agreement, and other good and valuable consideration, the receipt and sufficiency of which are hereby acknowledged, the Parties agree as follows: 

ARTICLE 1 

DEFINITIONS 
 1.1 Definitions. All capitalized terms not otherwise defined herein shall have the meaning given to them in the Collaboration Agreement. The following terms shall have the meanings set forth next
to them when used in this Agreement: 
 (a) “Co-Promotion Territory” means the United States of
America. 
 (b) “DDMAC” means the Division of Drug Marketing, Advertising and Communication of
the FDA. 
 (c) “Deficiency” means, for any Deficient Quarter, with respect to the applicable
Party, the percentage calculated using the following formula: ((A-B)/A), where A is the minimum number of PDEs assigned to such Party under the Collaboration Agreement or any then-current, mutually agreed upon Commercialization Plan for such
Calendar Quarter, and B is the number of PDEs actually delivered by the Sales Force of such Party during such Calendar Quarter. 

 (d) “Deficient Quarter” means, with respect to a Party, the
Calendar Quarter during which the Sales Force of such Party delivered fewer PDEs than the minimum number of PDEs assigned to such Party for such Calendar Quarter under the Collaboration Agreement or any then-current, mutually agreed upon
Commercialization Plan. 
 (e) “FD&C Act” means the United States Food, Drug and Cosmetic
Act, as amended from time to time (21 U.S.C. Section 301 et seq.), together with any rules and regulations promulgated thereunder. 
 (f) “Initial Three-Year Period” means the three (3) year period immediately following First Commercial Sale. 

(g) “Labeling” means (i) the FDA full prescribing information for Product in the Field, including
any required patient information, and (ii) all labels and other written, printed or graphic matter upon any container, wrapper or any package insert or outsert utilized with or for Product in the Field. 

(h) “PDMA” means the Prescription Drug Marketing Act of 1987, as amended from time to time, together with
any rules and regulations promulgated thereunder. 
 (i) “Promotion Related Activities” means
lunches, snacks, dinners, entertainment, or medically related gifts for health care professionals with prescribing authority used to promote Product to such persons. For purposes of this Agreement, Promotion Related Activities expressly excludes
conference or convention participation, continuing medical education programs, grants, paid speaker programs, symposiums and entertainment. 
 (j) “Samples” means quantities of Product given to authorized medical professionals for no or minimal consideration as part of the marketing, advertising and promotion of Product.

 (k) “Training Materials” means the items the JCC develops or approves after the Effective
Date to train persons to promote Product in the Co-Promotion Territory. 
 ARTICLE 2 

CO-PROMOTION RIGHTS AND OBLIGATIONS 
 2.1 Co-Promotion Right. As set forth herein and in the Collaboration Agreement, the Parties have the right and obligation to jointly Commercialize Product to Physician Targets for use in the Field
in the Co-Promotion Territory. 
 2.2 Performance. The Parties, through the JCC, will be responsible for the day-to-day
Commercialization activities for Product to Physician Targets for use in the Field in the Co-Promotion Territory. Subject to the terms of this Agreement and the Collaboration Agreement, the Parties shall have the right and responsibility to field
personnel and take actions related to Commercializing Product to Physician Targets for use in the Field in the Co-Promotion Territory during the Term, including the following: 

  
 2 

[***] Certain information in this document has been omitted and filed separately with the Securities and Exchange Commission. Confidential treatment
has been requested with respect to the omitted portions. 

 (a) Each Party shall perform its respective obligations under this
Agreement, the Collaboration Agreement and the Commercialization Plan. 
 (b) Following receipt of Regulatory
Approval of the Initial Indication in the Co-Promotion Territory, each Party shall use its Commercially Reasonable Efforts to Commercialize Product to Physician Targets in the Field in the Co-Promotion Territory and shall fulfill its obligations
under this Agreement and the Collaboration Agreement. The Parties shall deploy each of their respective Sales Forces in an effort to Commercialize Product to Physician Targets in the Field in the Co-Promotion Territory in accordance with the
Commercialization Plan in effect from time to time, the directions of the JCC, and the terms of this Agreement and the Collaboration Agreement. 
 (c) Exhibit A to this Agreement sets forth the calculations of the following items which shall be incorporated into the initial Commercialization Plan: minimum Calendar Quarter PDE requirements; PDE
Rate; Calendar Quarter PDE expenses at PDE minimums; and Calendar Quarter PDE caps. Upon mutual written agreement of the Parties, the items and calculations may be adjusted for purposes of preparing any new Commercialization Plans. In no event shall
a Party be entitled to include as a Shared Expense or in the calculation of Net Sales, or otherwise be entitled to reimbursement for, any PDE Cost amount in excess of the Calendar Quarter PDE caps set forth on Exhibit A (as may be amended from
time to time). Upon the adjustment of the PDE ratios as provided in the definition of “PDE”, the Parties shall mutually agree upon appropriate and equitable adjustments in the calculations of the items on Exhibit A to reflect such
changes. 
 (d) In implementing the obligations contained in this Agreement, each Party shall [***] (which shall
not be inconsistent with the Commercialization Plan, this Agreement and the Collaboration Agreement, and provided that neither Party will utilize any Promotional Materials not approved by the JCC) in which it promotes and Details (including any
expenditure of funds in connection therewith) Product in the Co-Promotion Territory. 
 (e) Neither Party shall
distribute or have distributed any information that bears the name or logo of the other Party without the prior approval of the other through the JSC or the JCC, which approval shall not be unreasonably withheld, conditioned or delayed. 

2.3 Joint Commercialization Activities. Subject to the requirements set forth in the Collaboration Agreement and the then-current
Commercialization Plan, each Party shall be responsible for performing Commercialization activities as described below: 
 (a) Commercialization Plan. In addition to those items set forth in Article 6 of the Collaboration Agreement and subject to the minimum obligations set forth herein and in the Collaboration
Agreement, the Commercialization Plan shall specify with respect to Commercialization to Physician Targets for use in the Field in the Co-Promotion Territory: 
 i. Promotional Materials to be used; 

  
 3 

[***] Certain information in this document has been omitted and filed separately with the Securities and Exchange Commission. Confidential treatment
has been requested with respect to the omitted portions. 

 ii. Subject to the minimum requirements set forth herein and in the
Collaboration Agreement, the number of PDEs that each Party and each respective Sales Force representative must perform in each Calendar Year; 
 iii. Detailing strategy and obligations of the Parties on a Calendar Year basis, including (a) the “call plan” size (i.e., the number of Physician Targets to be called on by each Sales
Force representative); (b) identification and prioritization of Physician Targets by deciles; (c) reach and frequency expectations for the Physician Targets in each Calendar Period; and (d) the number and position of PDEs for Product
to be performed in each Calendar Year; 
 iv. the reporting obligations of the Parties and their Sales Force
representatives with respect to the performance of their Commercialization activities under this Agreement, including the recording of Detailing activity by Sales Force representatives, the review by Sales Force representatives of the activities of
their counterparts on the other Party’s Sales Force, and the hardware, software and other information technology to be used therefor; 
 v. sales forecasts for Product on a Calendar Quarter basis (or more frequently if so determined by the Parties); 
 vi. compensation packages for sales representatives including incentive compensation; 
 vii. Product pricing strategy and managed care and reimbursement plans; 
 viii. budget for such activities; and 
 ix. such other plans
relating to Commercialization as the Parties deems necessary or appropriate. 
 (b) Sales Forces. The
Commercialization Plan will set forth in reasonable detail all material matters related to Sales Force activities with respect to Product to Physician Targets in the Field in the Co-Promotion Territory. Subject to and in accordance with the
provisions of this Agreement, the Collaboration Agreement and the Commercialization Plan, each Party shall: 
 i.
be solely responsible for recruiting, hiring, managing, maintaining, disciplining, firing, compensating (including paying for all benefits, wages, special incentives, workers’ compensation, and employment taxes) and otherwise controlling its
respective Sales Force and for paying for any and all costs associated with its Sales Force’s efforts; 

ii. provide the day-to-day management of its Sales Force, including, without limitation, furnishing administrative
support, financial resources, equipment, and supplies, monitoring detail reporting and Sample accounting, and assuring the Sales 

  
 4 

[***] Certain information in this document has been omitted and filed separately with the Securities and Exchange Commission. Confidential treatment
has been requested with respect to the omitted portions. 

 
Force’s understanding and compliance with this Agreement, the Collaboration Agreement, the Commercialization Plan and Applicable Laws; 

iii. utilize its Commercially Reasonable Efforts to deploy its Sales Force to Commercialize to Physician Targets for use
in the Field in the Co-Promotion Territory during the Term, after Regulatory Approval has been received for the Initial Indication for Product in the Field in the Co-Promotion Territory; and 

iv. for the avoidance of doubt, at all times be obligated to meet such Party’s minimum obligations as set forth in
the Collaboration Agreement. 
 (c) Training. The Parties shall establish procedures for jointly training
sales personnel and for preparation of Training Materials related to Commercialization of Product to Target Physicians in the Field in the Co-Promotion Territory. In addition, the Parties shall be responsible for preparing all sales Training
Materials with regard to Product to Physician Targets for use in the Field in the Co-Promotion Territory, such training to include a reasonable proficiency examination. Both Parties agree to utilize only sales Training Materials that have been
approved by each Party’s respective legal and regulatory departments. Training shall include a home study period and an initial classroom-setting training program, which shall include medical and technical information about use of Product in
the Field in the Co-Promotion Territory. The Parties shall direct which personnel shall receive training on the use of Product in the Field and which Party shall perform the training. Only personnel who have passed the proficiency examination with a
minimum [***] proficiency are qualified to Commercialize Product to Physician Targets for use in the Field in the Co-Promotion Territory. The Parties shall share training costs as set forth in the Collaboration Agreement. The Parties acknowledge
that their respective Sales Forces must be trained, qualified and ready to launch, Commercialize and Detail Product to Physician Targets for use in the Field in the Co-Promotion Territory on the date of launch as specified in the then-current
Commercialization Plan; provided that such date shall be no later than the date specified for such Party in the Collaboration Plan. 
 (d) Sales Force Meetings. The Parties will work together to coordinate the timing and location of Sales Force meetings regarding Product. The Parties shall have at least one (1) joint national
sales meeting per Calendar Year. If such national sales meeting involves products other than Product, ALLERGAN shall not have the right to participate in those sections that specifically relate to the other MAP products, and MAP shall not have the
right to participate in those sections that specifically relate to the other ALLERGAN products. The Parties shall share Sales Force meeting costs as set forth in the Collaboration Agreement. 

(e) Sales Territories. The sales territories, sales districts, and sales regions for the [***] sales territories,
sales districts and sales regions for [***]. If [***] its territories, sales districts or sales regions [***] shall in good faith consider the [***], but shall not be obligated to [***] for each state, territory, possession and protectorate within
the [***]. 
 (f) Samples. The Parties shall determine the appropriate level of and process for Product
sampling. MAP shall supply all Samples, the costs and expenses of which are included in Shared Expenses, subject to the provisions of the Collaboration Agreement. Each 

  
 5 

[***] Certain information in this document has been omitted and filed separately with the Securities and Exchange Commission. Confidential treatment
has been requested with respect to the omitted portions. 

 
Party will transport, store, handle and distribute all Samples, as may be determined by the Parties, in compliance with Applicable Laws and with the procedures established by the JCC. 

(g) Compensation. 
 i. Each Party shall use its Commercially Reasonable Efforts to ensure that variable pay components of its compensation structure, including but not limited to incentives (“Incentive
Compensation”), for its Sales Force with responsibility for Commercializing Product are consistent with practices used for other similar products. To facilitate the determination of Product incentives, the Parties will work together to
coordinate annual sales plans. 
 ii. In furtherance of and without limiting the foregoing, MAP shall allocate
[***] of Sales Force Incentive Compensation to Product for the shorter of [***], and [***]. 
 iii.
Notwithstanding anything contained in this Agreement or in the Collaboration Agreement, ALLERGAN will allocate [***] of ALLERGAN Sales Force Incentive Compensation to Product [***]. 

(h) Promotion of Other Products. Subject to the provisions of this Agreement, while this Agreement is in effect,
each Party has the right to have its Sales Force Detail products other than Product in any detail positions not reserved by the Parties for Product. [***]. 
 (i) Product Complaints. The Parties will establish appropriate procedures for handling and reporting of Product complaints. 

(j) Medical Inquiries. The Parties will establish appropriate procedures for dealing with medical inquiries related
to Product. 
 (k) Managed Care. The Parties shall coordinate activities with respect to Product across
managed care market segments in the Field in the Co-Promotion Territory including: (i) contract strategy, (ii) contract creation; (iii) government reporting, rebate processing, calculations and pricing schedules; (iv) contract
compliance, monitoring and audits; (v) contract administration and claims processing; and (vi) all other matters related to managed care. [***] to Detail or otherwise Commercialize Product to any Physician Targets or to any contracting
agents, medical directors, formulary decision makers, benefit managers, or administrators (even if such persons are health care professionals legally authorized to prescribe Product) of a managed care organization (e.g., health maintenance
organization, prescription benefits manager, insurance company, or similar entity), government-funded insurance or medical program, or employer. All Product Commercialization and contracting activities with managed care entities will be conducted by
the designated Party. 
 (l) Conflicts Between Agreements. For the avoidance of doubt and notwithstanding
any provision contained herein, in the Collaboration Agreement, or in the then-applicable Commercialization Plan, the minimum obligations set forth in any Commercialization 

  
 6 

[***] Certain information in this document has been omitted and filed separately with the Securities and Exchange Commission. Confidential treatment
has been requested with respect to the omitted portions. 

 
Plan shall equal or exceed the minimum obligations of the Parties, respectively, set forth in this Agreement and the Collaboration Agreement, unless expressly agreed upon in a written document
signed by both Parties. In the event of any discrepancy between this Agreement and the Collaboration Agreement, on the one hand, and any Commercialization Plan, on the other, the terms and conditions of this Agreement and the Collaboration Agreement
(taking into account the provisions of Section 7.1 hereof) shall control. 
 2.4 Consequences of Failure to Perform
Required PDEs. 
 (a) Detail Deficiencies. For any Deficient Quarter or Deficient Quarters in which a
Party’s Sales Force delivers fewer than [***] of the minimum PDEs assigned to it under the Collaboration Agreement or in the then-current, mutually agreed upon Commercialization Plan for such Calendar Quarter or Calendar Quarters: 

i. If a Party fails to perform at least [***] of the aggregate minimum required PDEs for Product for the then-current
Calendar Quarter, but performs at least [***] of such required PDEs, then the Party shall be entitled to carry such PDE Deficiencies forward to the following Calendar Quarter. Deficiencies that are carried forward to the next Calendar Quarter shall
be included in the calculation of the PDEs assigned in the successive Calendar Quarters, until satisfied in full. 
 ii. If a Party fails to perform at least [***] of the aggregate minimum required PDEs for Product for the then-current Calendar Quarter, then the other Party shall be entitled to a credit equal to the
difference between [***] of the minimum required PDEs and the actual PDEs performed, such number of PDEs then multiplied by [***], which shall be credited to the other Party’s share of Distributable Profit or Distributable Loss. 

(b) If either Party is more than [***] Deficient in [***], then such Party will be deemed to have not used Commercially
Reasonable Efforts in Commercializing Product and the other Party shall have the right to terminate this Agreement and the Collaboration Agreement upon written notice; provided, that any such termination shall not affect the right of the Party
terminating the Agreement from pursuing any and all other remedies that may be available to it. 
 (c) Each Party
shall be entitled to audit the records of the other Party (as well as the records of the other Party’s subcontractors) to verify such other Party’s delivery of PDEs under this Agreement pursuant to the audit provisions of the Collaboration
Agreement. 
 2.5 Promotional Materials. 

(a) The Parties shall establish a tracking system for Promotional Materials to ensure that all such Promotional Materials
are accurately tracked and submitted to the FDA. MAP will file all Promotional Materials with the FDA if, and as required, by FDA regulations. According to the agreed Commercialization Plan the JCC shall oversee the development and production of all
written, printed, electronic and graphic promotional materials including all product labels and inserts to be used by the Parties. Both Parties agree to utilize only 

  
 7 

[***] Certain information in this document has been omitted and filed separately with the Securities and Exchange Commission. Confidential treatment
has been requested with respect to the omitted portions. 

 
Promotional Materials that have been approved by each Party’s respective legal and regulatory departments. 

(b) The Parties shall not create, develop or distribute any sales, promotional content or other similar materials
(including Labeling) relating to Product for Commercialization to Target Physicians in the Field in the Co-Promotion Territory except as set forth in this Section. All oral communications that the Parties or its Sales Force has with Third Parties
relating to Product shall conform to the pre-approved talking points (which shall be the same for the Sales Force of both Parties) as recommended by the JCC and shall be subject to review by the JSC. 

2.6 Cessation of Use of Materials. If the Party responsible for Training Material, Promotional Material or Samples informs the JCC
in writing that a Training Material, Promotional Material, or Sample may no longer be used or distributed, each Party agrees that it will not allow its Sales Force to use or distribute such Training Material, Promotional Material, or Sample after
the no-use date identified by the responsible Party in its notice. 
 ARTICLE 3 

SALES AND EXPENSES 
 3.1 Sales and Distribution. Through the JCC, the Parties will establish the terms and conditions with respect to the Commercialization of Product to Physician Targets for use in the Field in the
Co-Promotion Territory, including, without limitation, [***]. 
 3.2 Sales Budget. As set forth in the Collaboration
Agreement, Sales Force members shall be reimbursed at an FTE Rate equal to [***] per FTE, which amount may be subject to change from time to time during the Term upon mutual agreement of the Parties. 

ARTICLE 4 

OPERATING PROCEDURES 
 4.1 Exchange of Information. 
 (a) Exchange of
Information Generally. Each Party shall provide the other Party with such information as the other Party may reasonably request during the Term in order to support the requesting Party’s Sales Force’s Commercialization and Detailing of
Product to Physician Targets for use in the Field in the Co-Promotion Territory. During the Term and subject to the provisions of this Agreement, each Party will provide the other with all information that the disclosing Party reasonably deems
significant and relevant to the Commercialization and Detailing of Product to Physician Targets for use in the Field in the Co-Promotion Territory within a reasonable time after such information becomes known to the Party; provided, however, that
such information is not received from an independent Third Party under a confidentiality obligation. The JCC shall establish reasonable procedures for monitoring of Sales Force activities to ensure that each Party is complying with its obligations
under this Agreement. 

  
 8 

[***] Certain information in this document has been omitted and filed separately with the Securities and Exchange Commission. Confidential treatment
has been requested with respect to the omitted portions. 

 (b) Electronic Reporting. The Parties shall utilize an electronic
sales force automation system for data collection and data management consistent with industry standard practices to produce reports and analyses of their respective Sales Force’s activities and Product performance with Physician Targets in the
Field in the Co-Promotion Territory. The Parties shall provide an electronic call reporting system to each member of their respective Sales Force. The deployed system shall be in compliance with Applicable Laws. Each Sales Force member shall produce
detailed electronic notes following each Detail. Each Sales Force member shall be responsible for Detail planning and Detail routing, using sales data to plan, monitor and measure territory performance, as well as reporting useful marketing
information obtained for Product in the Co-Promotion Territory, [***]. Within thirty (30) days after the end of each calendar month, the Parties will share reports summarizing Sales Force activity collected from such electronic call reporting
system(s) in the prior calendar month. Specific reportable information shall at a minimum include: (i) total number of PDEs reported for each Sales Force member, by month, by Calendar Quarter and year-to-date; (ii) aggregate PDEs by month,
by Calendar Quarter and year-to-date to each unique member of Physician Targets; and (iii) roll-up of each Party’s monthly, Calendar Quarter and year-to-date aggregate PDEs versus the monthly, by Calendar Quarter and year-to-date goal as
specified in the then-current Commercialization Plan. Such information shall be reported in a Microsoft Excel electronic file format or such other format as reasonably agreed by the Parties. 

(c) Other Reporting. The Parties shall report to each other all information necessary to permit each Party to make
timely reports as required by any governmental regulatory agency regarding Product. Each Party shall promptly communicate to the other Party all comments, statements, requests and inquiries of the medical profession or any other Third Parties
relating to Product in the Field in the Co-Promotion Territory that are out of the ordinary, or not covered by the Labeling, of which such Party becomes aware. All responses to such inquiries of the medical profession or such other Third Parties
within the Co-Promotion Territory shall be handled as designated by the JCC. The Parties shall refer all medical inquiries concerning Product in the Field and all quality complaints within the Co-Promotion Territory to a designated address and/or
telephone number agreed upon by the Parties. 
 4.2 Compliance. 

(a) The Parties shall conform their practices and procedures relating to Commercializing and Detailing of Product in the
Field in the Co-Promotion Territory to policies and procedures, as determined by the JCC from time to time (the “Policies”), but in no event less than the requirements of all applicable Laws and guidelines, including the FD&C
Act, the PDMA, the requirements of DDMAC, the Federal Health Care Programs Anti-Kickback Law, 42 U.S.C. 1320a-7b(b), the Pharmaceutical Research and Manufacturers of America (“PhRMA”) Code of Pharmaceutical Marketing Practices
(the “PhRMA Code”) and the American Medical Association (“AMA”) Guidelines on Gifts to Physicians from Industry (the “AMA Guidelines”), as the same may be amended from time to time. Each Party shall
promptly notify the other Party of and provide the other Party with a copy of any correspondence or other reports with respect to Commercializing, Detailing and/or promotion of Product in the Field in the Co-Promotion Territory submitted to or
received from the U.S. Department of Health and 

  
 9 

[***] Certain information in this document has been omitted and filed separately with the Securities and Exchange Commission. Confidential treatment
has been requested with respect to the omitted portions. 

 
Human Services or its components (including the FDA and the Office of the Inspector General), PhRMA or the AMA relating to such Laws and guidelines. 

(b) The Parties shall in all material respects conform their practices and procedures relating to educating the medical
community in the Co-Promotion Territory with respect to Product in the Field in the Co-Promotion Territory to the Policies, the Accreditation Council for Continuing Medical Education (“ACCME”) Standards for Commercial Support of
Continuing Medical Education (the “ACCME Standards”) and any applicable FDA regulations or guidelines, as the same may be amended from time to time. Each Party shall promptly notify the other Party of and provide the other Party
with a copy of any correspondence or other reports submitted to or received from the ACCME with respect to Product in the Field in the Co-Promotion Territory relating to the ACCME Standards or such FDA regulations or guidelines. 

(c) The Parties shall provide each member of its Sales Force (prior to performance of services hereunder), with a copy of
the then-current code of ethics of the respective Party. The Parties shall ensure that each member of its Sales Force acknowledges in writing receipt of, and will comply with, the then-current code of ethics in performing services under this
Agreement and the Collaboration Agreement. 
 (d) In connection with Commercialization and Detailing of Product
hereunder, neither Party nor any member(s) of their respective Sales Forces shall knowingly make any false or misleading statement, or make any representation or warranty, oral or written, to Third Parties, concerning Product that is inconsistent
with, or contrary to, the Labeling or Promotional Materials or that is disparaging to Product, the other Party, or any of other Party’s Affiliates, officers, directors or employees. 

4.3 Independent Contractors. For all purposes, and notwithstanding any other provisions of this Agreement to the contrary, the
legal relationship under this Agreement of the Parties shall be that of independent contractors. It is further understood and agreed that the Parties are engaged in the operation of their own respective businesses, and neither Party is to be
considered the agent of the other Party for any purpose whatsoever. Neither Party will have any authority to enter into any contracts or assume any obligations for the other Party nor make any warranties or representations on behalf of that other
Party. 
 ARTICLE 5 
 REPRESENTATIONS, WARRANTIES AND COVENANTS 
 5.1 The Parties’
Representations and Warranties. Each Party hereby represents, warrants and covenants to the other Party that: 
 (a) it is not debarred under the Generic Drug Enforcement Act of 1992 (the “GDE Act”) and is in compliance with the provisions of the GDE Act; 

(b) while this Agreement is in effect, it will comply with the GDE Act, will not become debarred under the GDE Act, and
will not use in connection with this Agreement the services of any person or entity debarred under the GDE Act; 

  
 10 

[***] Certain information in this document has been omitted and filed separately with the Securities and Exchange Commission. Confidential treatment
has been requested with respect to the omitted portions. 

 (c) upon request by the other Party, a Party will certify its compliance
with the GDE Act and this Section in writing to such other Party; 
 (d) no employee or representative of a Party
shall have any authority to bind or obligate the other Party to this Agreement for any sum or in any manner whatsoever, or to create or impose any contractual or other liability on the other Party without the other Party’s authorized written
approval. 
 5.2 MAP Representations, Warranties, and Covenants. MAP represents, warrants and covenants that: 

(a) MAP has or shall have at the time required the requisite personnel, facilities, equipment, expertise, experience and
skill to perform its obligations hereunder and to render the services contemplated hereby; 
 (b) MAP and its
Sales Force shall perform the services in a professional, timely, competent and efficient manner, and it and its Sales Force shall abide by all Laws that apply to its and their performance; 

(c) any negligent or wrongful act or omission on the part of MAP’s Sales Force (both individually and as a group)
shall be deemed to be negligent or wrongful acts or omissions of MAP. MAP shall notify ALLERGAN in writing as promptly as practicable of any alleged negligent or wrongful acts or omissions on the part of MAP’s Sales Force, and of any
allegations of negligent or wrongful acts or omissions made against ALLERGAN’s Sales Force; and 
 (d) at
the time MAP delivers Samples to ALLERGAN, MAP represents and warrants to ALLERGAN that such Samples: 
 i.
comply in all material respects with the Product Specifications; 
 ii. comply in all material respects with the
FD&C Act; 
 iii. are not products that have been adulterated or misbranded within the meaning set forth in
FD&C Act and any state or local law or regulation substantially similar to FD&C Act; 
 iv. are products
that may be introduced into interstate commerce; and 
 v. have been manufactured, packaged, stored, and shipped
in conformity with all applicable cGMP. 
 5.3 ALLERGAN Warranties and Covenants. ALLERGAN warrants and covenants that:

  
 11 

[***] Certain information in this document has been omitted and filed separately with the Securities and Exchange Commission. Confidential treatment
has been requested with respect to the omitted portions. 

 (a) ALLERGAN has the requisite personnel, facilities, equipment, expertise,
experience and skill to perform its obligations hereunder and to render the services contemplated hereby; 
 (b)
ALLERGAN and its Sales Force shall perform such services in a professional, timely, competent and efficient manner, and it and its Sales Force shall abide by all Applicable Laws that apply to its and their performance; and 

(c) any negligent or wrongful act or omission on the part of ALLERGAN’s Sales Force (both individually and as a
group) shall be deemed to be negligent or wrongful acts or omissions of ALLERGAN. ALLERGAN shall notify MAP in writing as promptly as practicable of any alleged negligent or wrongful acts or omissions on the part of ALLERGAN’s Sales Force, and
of any allegations of negligent or wrongful acts or omissions made against MAP’s Sales Force. 
 5.4 Notice of
Breach. If, at any time, a Party is aware that it has materially breached a representation, warranty or covenant under this Agreement, the breaching Party will promptly notify the other Party of such material breach. 

5.5 Performance by Affiliates. The Parties recognize that a Party may perform some or all of its obligations under this Agreement
through its Affiliates. 
 5.6 DISCLAIMER OF ALL OTHER WARRANTIES. THE WARRANTIES SET FORTH IN THIS AGREEMENT AND THE
COLLABORATION AGREEMENT ARE THE PARTIES’ ONLY WARRANTIES WITH RESPECT HERETO AND ARE MADE EXPRESSLY IN LIEU OF ALL OTHER WARRANTIES, EXPRESS OR IMPLIED, WHICH ARE HEREBY DISCLAIMED, INCLUDING ANY IMPLIED WARRANTIES OF FITNESS FOR A PARTICULAR
PURPOSE, MERCHANTABILITY, OR OTHERWISE. 
 5.7 LIMITATION OF LIABILITY. WITHOUT LIMITING THE PARTIES’
INDEMNIFICATION OBLIGATIONS UNDER THE COLLABORATION AGREEMENT, NEITHER PARTY SHALL BE LIABLE TO THE OTHER PARTY FOR SPECIAL, INDIRECT, INCIDENTAL, PUNITIVE, OR CONSEQUENTIAL DAMAGES (INCLUDING WITHOUT LIMITATION DAMAGES RESULTING FROM LOSS OF USE,
LOSS OF PROFITS, INTERRUPTION OR LOSS OF BUSINESS, OR OTHER ECONOMIC LOSS) ARISING OUT OF THIS AGREEMENT OR WITH RESPECT TO A PARTY’S PERFORMANCE OR NON-PERFORMANCE HEREUNDER. 

ARTICLE 6 

TERM AND TERMINATION 
 6.1 Term. The term of this Agreement shall commence on the Effective Date and continue until the earlier of (a) termination of the Collaboration Agreement or (b) the date on which this
Agreement is terminated pursuant to the provisions herein (the “Term”). 
 6.2 Effect of Termination or
Expiration. Termination or expiration of this Agreement in whole or in part shall not relieve the Parties of any amounts owing between them 

  
 12 

[***] Certain information in this document has been omitted and filed separately with the Securities and Exchange Commission. Confidential treatment
has been requested with respect to the omitted portions. 

 
at the date termination or expiration. Upon termination or expiration of this Agreement, ALLERGAN shall, at its sole expense and within thirty (30) days of such termination or expiration,
return to MAP all Promotional Materials and any Samples of Product then in the possession of ALLERGAN and any of its Sales Force; provided, however, that ALLERGAN shall be entitled to retain one (1) copy of such Promotional Materials,
(a) to the extent reasonably required to allow ALLERGAN to carry out any remaining obligations under this Agreement or the Collaboration Agreement or to exercise any of its rights that expressly survive termination or expiration of this
Agreement or the Collaboration Agreement, and (b) for legal archival purposes and/or as may be required by Applicable Law. The following provisions shall survive any termination or expiration of this Agreement: Articles 1 and 7 and
Sections 2.3(l), 5.6, 5.7 and 6.2. 
 ARTICLE 7 

GENERAL PROVISIONS 
 7.1 Incorporation of Terms from the Collaboration Agreement. This Agreement forms an integral part of the Collaboration Agreement, and is incorporated into the Collaboration Agreement. As a part of
the Collaboration Agreement, this Agreement is subject to all terms and conditions of the Collaboration Agreement. Without limiting the generality of the foregoing, Article 6 and Article 18 of the Collaboration Agreement each apply to this
Agreement as if stated herein. In the event of any contradictions or inconsistencies between the terms of this Agreement and those of the Collaboration Agreement, the terms of the Collaboration Agreement shall govern. 

7.2 Addition of Canada to Territory. The Parties acknowledge and agree that if Canada becomes part of the Territory in accordance
with the terms of the Collaboration Agreement, the Parties or their respective Affiliates will enter into a separate co-promotion agreement with respect to Canada, or amend this Agreement to include terms that are specific to Canada and the
Parties’ (or their respective Affiliates’) obligations with respect to promotion of Product in Canada, in accordance with the Collaboration Agreement. 

  
 13 

[***] Certain information in this document has been omitted and filed separately with the Securities and Exchange Commission. Confidential treatment
has been requested with respect to the omitted portions. 

 In Witness Whereof, the Parties have as of the date first set forth above duly
executed this Agreement. 
  

									
	ALLERGAN USA, INC.	 		 	MAP PHARMACEUTICALS, INC.
					
	By: 	 	 /s/  David E.I. Pyott
	 		 	By:	 	 /s/  Timothy S. Nelson

					
	Name:	 	 David E.I. Pyott
	 		 	Name:	 	 Timothy S. Nelson

					
	Title: 	 	 Chief Executive Officer
	 		 	Title: 	 	 President and CEO

  
 [***] Certain information
in this document has been omitted and filed separately with the Securities and Exchange Commission. Confidential treatment has been requested with respect to the omitted portions. 

 EXHIBIT A 
 Calculations for Certain Items in Initial Commercialization Plan 
  

									
	 	  	Allergan	 	  	MAP	 
			
	 Minimum Calendar Quarter PDE Requirements
	  	 	[***]	  	  	 	[***]	  
			
	 PDE Rates
	  	 	[***]	  	  	 	[***]	  
			
	 Calendar Quarter PDE Expense at PDE Minimum
	  	 	[***]	  	  	 	[***]	  
			
	 Calendar Quarter PDE Expense Cap
	  	 	[***]	  	  	 	[***]	  

  
 [***] Certain information
in this document has been omitted and filed separately with the Securities and Exchange Commission. Confidential treatment has been requested with respect to the omitted portions.Fifty-First Supplemental Indenture

 Exhibit 4.1 
 CONFORMED COPY 
  
  

 
 AVISTA CORPORATION

 TO 
 CITIBANK, N.A. 
 As Successor Trustee under 

Mortgage and Deed of Trust, 
 dated as of June 1, 1939 
  

 
 Fifty-first
Supplemental Indenture 
 Providing among other things for a series of bonds designated 

“First Mortgage Bonds, Collateral Series 2011A” 
 Due February 11, 2015
  

 
 Dated as of
February 1, 2011 
  
  

 

 FIFTY-FIRST SUPPLEMENTAL INDENTURE 

THIS INDENTURE, dated as of the 1st day of February, 2011, between AVISTA CORPORATION (formerly known as The
Washington Water Power Company), a corporation of the State of Washington, whose post office address is 1411 East Mission Avenue, Spokane, Washington 99202 (the “Company”), and CITIBANK, N.A., formerly First National City Bank (successor
by merger to First National City Trust Company, formerly City Bank Farmers Trust Company), a national banking association incorporated and existing under the laws of the United States of America, whose post office address is 388 Greenwich Street,
14th Floor, New York, New York 10013 (the
“Trustee”), as Trustee under the Mortgage and Deed of Trust, dated as of June 1, 1939 (the “Original Mortgage”), executed and delivered by the Company to secure the payment of bonds issued or to be issued under and in
accordance with the provisions thereof, this indenture (the “Fifty-first Supplemental Indenture”) being supplemental to the Original Mortgage, as heretofore supplemented and amended. 

WHEREAS pursuant to a written request of the Company made in accordance with Section 103 of the Original Mortgage, Francis M. Pitt
(then Individual Trustee under the Mortgage, as supplemented) ceased to be a trustee thereunder on July 23, 1969, and all of his powers as Individual Trustee have devolved upon the Trustee and its successors alone; and 

WHEREAS by the Original Mortgage the Company covenanted that it would execute and deliver such further instruments and do such further
acts as might be necessary or proper to carry out more effectually the purposes of the Original Mortgage and to make subject to the lien of the Original Mortgage any property thereafter acquired intended to be subject to the lien thereof; and

 WHEREAS the Company has heretofore executed and delivered, in addition to the Original Mortgage, the indentures supplemental
thereto, and has issued the series of bonds, set forth in Exhibit A hereto (the Original Mortgage, as supplemented and amended by the First through Fiftieth Supplemental Indentures, being herein sometimes called the “Mortgage”); and

 WHEREAS the Original Mortgage and the First through Forty-seventh Supplemental Indentures have been appropriately filed or
recorded in various official records in the States of Washington, Idaho, Montana and Oregon, as set forth in the First through Forty-eighth Supplemental Indentures and the Instrument of Further Assurance, dated December 15, 2001, hereinafter
referred to; and 
 WHEREAS the Forty-eighth Supplemental Indenture, the Forty-ninth Supplemental Indenture and the Fiftieth
Supplemental Indenture, each dated as of December 1, 2010, are being appropriately filed or recorded in the States of Washington, Idaho, Montana and Oregon, information as to such filing and recording to be set forth in a subsequent
supplemental indenture; and 
 WHEREAS for the purpose of confirming or perfecting the lien of the Mortgage on certain of its
properties, the Company has heretofore executed and delivered a Short Form Mortgage and Security Agreement, in multiple counterparts dated as of various dates in 1992, and such instrument has been appropriately filed or recorded in the various
official records in the States of Montana and Oregon; and 

  
 2 

 WHEREAS for the purpose of confirming or perfecting the lien of the Mortgage on certain of
its properties, the Company has heretofore executed and delivered an Instrument of Further Assurance, dated as of December 15, 2001, and such instrument has been appropriately filed or recorded in the various official records in the States of
Washington, Idaho, Montana and Oregon; and 
 WHEREAS in addition to the property described in the Mortgage the Company has
acquired certain other property, rights and interests in property; and 
 WHEREAS Section 120 of the Original Mortgage, as
heretofore amended, provides that, without the consent of any holders of bonds, the Company and the Trustee, at any time and from time to time, may enter into indentures supplemental to the Original Mortgage for various purposes set forth therein,
including, without limitation, to cure ambiguities or correct defective or inconsistent provisions or to make other changes therein that shall not adversely affect the interests of the holders of bonds of any series in any material respect or to
establish the form or terms of bonds of any series as contemplated by Article II; and 
 WHEREAS Section 8 of the Original
Mortgage, as heretofore amended, provides that the form of each series of bonds (other than the First Series) issued thereunder and of the coupons to be attached to coupon bonds of such series shall be established by Resolution of the Board of
Directors of the Company or by Treasurer’s Certificate, or shall be set forth in an indenture supplemental to the Original Mortgage; that the form of such series, as so established, shall specify the descriptive title of the bonds and various
other terms thereof; and that such series may also contain such provisions not inconsistent with the provisions of the Mortgage as the Company may, in its discretion, cause to be inserted therein expressing or referring to the terms and conditions
upon which such bonds are to be issued and/or secured under the Mortgage; and 
 WHEREAS the Company now desires to create a new
series of bonds; and 
 WHEREAS the execution and delivery by the Company of this Fifty-first Supplemental Indenture and the
terms of the Bonds of the Fifty-third Series, hereinafter referred to, have been duly authorized by the Board of Directors of the Company by appropriate Resolutions of said Board of Directors; and all things necessary to make this Fifty-first
Supplemental Indenture a valid, binding and legal instrument have been performed; 
 NOW, THEREFORE, THIS INDENTURE WITNESSETH:
That the Company, in consideration of the premises and of other good and valuable consideration, the receipt and sufficiency whereof are hereby acknowledged, hereby confirms the estate, title and rights of the Trustee (including, without limitation,
the lien of the Mortgage on the property of the Company subjected thereto, whether now owned or hereafter acquired) held as security for the payment of both the principal of and interest and premium, if any, on the bonds from time to time issued
under the Mortgage according to their tenor and effect and the performance of all the provisions of the Mortgage and of such bonds, and, without limiting the generality of the foregoing, hereby

  
 3 

 
confirms the grant, bargain, sale, release, conveyance, assignment, transfer, mortgage, pledge, setting over and confirmation unto the Trustee, contained in the Mortgage, of all the following
described properties of the Company, whether now owned or hereafter acquired, namely: 
 All of the property,
real, personal and mixed, of every character and wheresoever situated (except any hereinafter or in the Mortgage expressly excepted) which the Company now owns or, subject to the provisions of Section 87 of the Original Mortgage, may hereafter
acquire prior to the satisfaction and discharge of the Mortgage, as fully and completely as if herein or in the Mortgage specifically described, and including (without in anywise limiting or impairing by the enumeration of the same the scope and
intent of the foregoing or of any general description contained in Mortgage) all lands, real estate, easements, servitudes, rights of way and leasehold and other interests in real estate; all rights to the use or appropriation of water, flowage
rights, water storage rights, flooding rights, and other rights in respect of or relating to water; all plants for the generation of electricity, power houses, dams, dam sites, reservoirs, flumes, raceways, diversion works, head works, waterways,
water works, water systems, gas plants, steam heat plants, hot water plants, ice or refrigeration plants, stations, substations, offices, buildings and other works and structures and the equipment thereof and all improvements, extensions and
additions thereto; all generators, machinery, engines, turbines, boilers, dynamos, transformers, motors, electric machines, switchboards, regulators, meters, electrical and mechanical appliances, conduits, cables, pipes and mains; all lines and
systems for the transmission and distribution of electric current, gas, steam heat or water for any purpose; all towers, mains, pipes, poles, pole lines, conduits, cables, wires, switch racks, insulators, compressors, pumps, fittings, valves and
connections; all motor vehicles and automobiles; all tools, implements, apparatus, furniture, stores, supplies and equipment; all franchises (except the Company’s franchise to be a corporation), licenses, permits, rights, powers and privileges;
and (except as hereinafter or in the Mortgage expressly excepted) all the right, title and interest of the Company in and to all other property of any kind or nature. 
 TOGETHER WITH all and singular the tenements, hereditaments and appurtenances belonging or in anywise appertaining to the aforesaid property or any part thereof, with the reversion and reversions,
remainder and remainders and (subject to the provisions of Section 57 of the Original Mortgage) the tolls, rents, revenues, issues, earnings, income, product and profits thereof, and all the estate, right, title and interest and claim
whatsoever, at law as well as in equity, which the Company now has or may hereafter acquire in and to the aforesaid property and franchises and every part and parcel thereof. 
 THE COMPANY HEREBY CONFIRMS that, subject to the provisions of Section 87 of the Original Mortgage, all the property, rights, and franchises acquired by the Company after the date thereof (except any
hereinbefore or hereinafter or in the Mortgage expressly excepted) are and shall be as fully embraced within the lien of the Mortgage as if such property, rights and franchises had been owned by the Company at the date of the Original Mortgage and
had been specifically described therein. 

  
 4 

 PROVIDED THAT the following were not and were not intended to be then or now or hereafter
granted, bargained, sold, released, conveyed, assigned, transferred, mortgaged, pledged, set over or confirmed under the Mortgage and were, are and shall be expressly excepted from the lien and operation of the Mortgage namely: (l) cash, shares
of stock and obligations (including bonds, notes and other securities) not hereafter specifically pledged, paid, deposited or delivered under the Mortgage or covenanted so to be; (2) merchandise, equipment, materials or supplies held for the
purpose of sale in the usual course of business or for consumption in the operation of any properties of the Company; (3) bills, notes and accounts receivable, and all contracts, leases and operating agreements not specifically pledged under
the Mortgage or covenanted so to be; (4) electric energy and other materials or products generated, manufactured, produced or purchased by the Company for sale, distribution or use in the ordinary course of its business; and (5) any
property heretofore released pursuant to any provisions of the Mortgage and not heretofore disposed of by the Company; provided, however, that the property and rights expressly excepted from the lien and operation of the Mortgage in the above
subdivisions (2) and (3) shall (to the extent permitted by law) cease to be so excepted in the event that the Trustee or a receiver or trustee shall enter upon and take possession of the Mortgaged and Pledged Property in the manner
provided in Article XII of the Original Mortgage by reason of the occurrence of a Completed Default as defined in said Article XII. 
 TO HAVE AND TO HOLD all such properties, real, personal and mixed, granted, bargained, sold, released, conveyed, assigned, transferred, mortgaged, pledged, set over or confirmed by the Company in the
Mortgage as aforesaid, or intended so to be, unto the Trustee, and its successors, heirs and assigns forever. 
 IN TRUST
NEVERTHELESS, for the same purposes and upon the same terms, trusts and conditions and subject to and with the same provisos and covenants as set forth in the Mortgage, this Fifty-first Supplemental Indenture being supplemental to the Mortgage.

 AND IT IS HEREBY FURTHER CONFIRMED by the Company that all the terms, conditions, provisos, covenants and provisions
contained in the Mortgage shall affect and apply to the property in the Mortgage described and conveyed, and to the estates, rights, obligations and duties of the Company and the Trustee and the beneficiaries of the trust with respect to said
property, and to the Trustee and its successors in the trust, in the same manner and with the same effect as if the said property had been owned by the Company at the time of the execution of the Original Mortgage, and had been specifically and at
length described in and conveyed to said Trustee by the Original Mortgage as a part of the property therein stated to be conveyed. 

  
 5 

 The Company further covenants and agrees to and with the Trustee and its successor or
successors in such trust under the Mortgage, as follows: 
 ARTICLE I 

Fifty-third Series of Bonds 
 SECTION 1. (I) There shall be a series of bonds designated “Collateral Series 2011A” (herein sometimes referred to as the “Bonds of the Fifty-third Series”), each of which shall also
bear the descriptive title First Mortgage Bond, and the form thereof, is set forth on Exhibit B hereto. Bonds of the Fifty-third Series shall be issued as fully registered bonds in denominations of One Thousand Dollars and, at the option of the
Company, any amount in excess thereof (the exercise of such option to be evidenced by the execution and delivery thereof) and shall be dated as in Section 10 of the Original Mortgage provided. Each Bond of the Fifty-third Series shall mature on
February 11, 2015 (or such later date to which such Stated Maturity shall have been extended as provided below) and shall bear interest, be redeemable and have such other terms and provisions as set forth below. 

(II) The Bonds of the Fifty-third Series shall have the following terms and characteristics: 

(a) the Bonds of the Fifty-third Series shall be initially authenticated and delivered under the Mortgage in the aggregate
principal amount of $400,000,000; 
 (b) the Bonds of the Fifty-third Series shall bear interest at the rate of
eight per centum (8%) per annum; interest on such Bonds shall accrue from and including the date of the initial authentication and delivery thereof, except as otherwise provided in the form of Bond attached hereto as Exhibit B; interest on such
Bonds shall be payable on each Interest Payment Date and at Maturity (as each of such terms is hereinafter defined); and interest on such Bonds during any period less than one year for which payment is made shall be computed in accordance with the
Credit Agreement (as hereinafter defined); 
 (c) the principal of and premium, if any, and interest on each Bond
of the Fifty-third Series payable at Maturity shall be payable upon presentation thereof at the office or agency of the Company in the Borough of Manhattan, The City of New York, in such coin or currency as at the time of payment is legal tender for
public and private debts; and the interest on each Bond of the Fifty-third Series (other than interest payable at Maturity) shall be payable directly to the registered owner thereof; 

(d) the Bonds of the Fifty-third Series shall not be redeemable, in whole or in part, at the option of the Company;

 (e) (i) the Bonds of the Fifty-third Series are to be issued and delivered to the Administrative Agent (as
hereinafter defined) in order to provide the benefit of the lien of the Mortgage as security for the obligation of the Company under the Credit Agreement to pay the Obligations (as hereinafter defined), to the extent and subject to the limitations
set forth in clauses (iii) and (iv) of this subdivision; 
 (ii) upon the earliest of (A) the
occurrence of an Event of Default (as hereinafter defined), and further upon the condition that, in accordance with the terms of the Credit Agreement, the Commitments (as so defined) shall have been or shall have terminated and any Loans (as so
defined) outstanding shall have been declared to be or shall have otherwise become due and payable immediately and the Administrative Agent shall have demanded that the Company provide cash collateral in the amount of the total LC Exposure (as so
defined) and the Administrative Agent shall have delivered to the 

  
 6 

 
Company a notice demanding redemption of the Bonds of the Fifty-third Series which notice states that it is being delivered pursuant to Article VII of the Credit Agreement; (B) the
occurrence of an Event of Default under clause (g) or (h) of Article VII of the Credit Agreement; and (C) the Stated Maturity, then all Bonds of the Fifty-third Series shall be redeemed or paid immediately at the principal
amount thereof plus accrued interest to the date of redemption or payment; 
 (iii) the obligation of the Company
to pay the accrued interest on Bonds of the Fifty-third Series on any Interest Payment Date prior to Maturity (a) shall be deemed to have been satisfied and discharged in full in the event that all amounts then due in respect of the Obligations
shall have been paid or (b) shall be deemed to remain unsatisfied in an amount equal to the aggregate amount then due in respect of the Obligations and remaining unpaid (not in excess, however, of the amount otherwise then due in respect of
interest on the Bonds of the Fifty-third Series); 
 (iv) the obligation of the Company to pay the principal of
and accrued interest on Bonds of the Fifty-third Series at or after Maturity (x) shall be deemed to have been satisfied and discharged in full in the event that all amounts then due in respect of the Obligations shall have been paid or
(y) shall be deemed to remain unsatisfied in an amount equal to the aggregate amount then due in respect of the Obligations and remaining unpaid (not in excess, however, of the amount otherwise then due in respect of principal of and accrued
interest on the Bonds of the Fifty-third Series). 
 (v) the Trustee shall be entitled to presume that the
obligation of the Company to pay the principal of and interest on the Bonds of the Fifty-third Series as the same shall become due and payable shall have been fully satisfied and discharged unless and until it shall have received a written notice
from the Administrative Agent, signed by an authorized officer thereof, stating that the principal of and/or interest on the Bonds of the Fifty-third Series has become due and payable and has not been fully paid, and specifying the amount of funds
required to make such payment; 
 (f) no service charge shall be made for the registration of transfer or
exchange of Bonds of the Fifty-third Series; 
 (g) in the event of an application by the Administrative Agent
for a substituted Bond of the Fifty-third Series pursuant to Section 16 of the Original Mortgage, the Administrative Agent shall not be required to provide any indemnity or pay any expenses or charges as contemplated in said Section 16;
and 
 (h) if the Expiration Date shall have been extended pursuant to Section 2.20 of the Credit Agreement,
and if the Company shall have furnished to the Trustee written evidence of such extension, executed by the Administrative Agent, the Stated Maturity shall, without further act, be deemed to have been extended to the Expiration Date (as so extended).

 (i) the Bonds of the Fifty-third Series shall have such other terms as are set forth in the form of bond
attached hereto as Exhibit B. 

  
 7 

 Anything in this Fifty-first Supplemental Indenture or in the Bonds of the Fifty-third
Series to the contrary notwithstanding, if, at the time of the Maturity of the Bonds of the Fifty-third Series, the stated aggregate principal amount of such Bonds then Outstanding shall exceed the aggregate Commitments (as hereinafter defined), the
aggregate principal amount of such Bonds shall be deemed to have been reduced by the amount of such excess. 
 (III) For all
purposes of this Article I, except as otherwise expressly provided or unless the context otherwise requires, the terms defined below shall have the meanings specified: 

“Administrative Agent” means Union Bank, N.A., in its capacity as Administrative Agent under the Credit
Agreement. 
 “Bond Delivery Agreement” means the Bond Delivery Agreement, dated
February 11, 2011 between the Company and the Administrative Agent. 
 “Commitments” shall
have the meaning specified in the Credit Agreement. 
 “Credit Agreement” means the Credit
Agreement, dated as of February 11, 2011, among the Company, the lenders party thereto, The Bank of New York Mellon, KeyBank National Association and U.S. Bank National Association, as Co-Documentation Agents, Wells Fargo Bank, National
Association, as Syndication Agent and an Issuing Bank, and Union Bank, N.A., as Administrative Agent and an Issuing Bank. 
 “Event of Default” shall have the meaning specified in the Credit Agreement. 
 “Expiration Date” shall have the meaning specified in the Credit Agreement. 
 “Interest Payment Date” means March 31, June 30, September 30 and December 31. 

“LC Exposure” shall have the meaning specified in the Credit Agreement. 

“Loans” shall have the meaning specified in the Credit Agreement. 

“Maturity” means the date on which the principal of the Bonds of the Fifty-third Series becomes due and
payable, whether at stated maturity, upon redemption or acceleration or otherwise. 

“Obligations” shall have the meaning specified in the Bond Delivery Agreement. 

“Stated Maturity” means February 11, 2015 or such later date to which such date shall have been
extended as provided in subsection II(h) above. 
 A copy of the Credit Agreement is on file at the office of the Administrative
Agent at 445 South Figueroa Street, Los Angeles, CA 90071 and at the office of the Company at 1411 East Mission Avenue, Spokane, WA 99202. 

  
 8 

 ARTICLE II 
 Outstanding Bonds 
 Upon the delivery of this Fifty-first Supplemental
Indenture, Bonds of the Fifty-third Series in the aggregate principal amount of $400,000,000 are to be issued and will be Outstanding, in addition to $1,178,700,000 aggregate principal amount of bonds of prior series Outstanding at the date of
delivery of this Fifty-first Supplemental Indenture (which amount excludes $320,000,000 in aggregate principal amount of First Mortgage Bonds, Collateral Series due 2011, and $75,000,000 in aggregate principal amount of First Mortgage
Bonds, Collateral Series 2009A, to be retired simultaneously with the issuance and delivery of the Bonds of the Fifty-third Series); it being understood that, subject to the provisions of the Mortgage, there shall be no limit upon the aggregate
principal amount of Bonds of the Fifty-third Series which may be authenticated and delivered hereunder. 
 ARTICLE III

 Miscellaneous Provisions 
 SECTION 1. The terms defined in the Original Mortgage shall, for all purposes of this Fifty-first Supplemental Indenture, have the meanings specified in the Original Mortgage. 

SECTION 2. The Trustee hereby confirms its acceptance of the trusts in the Original Mortgage declared, provided, created or supplemented
and agrees to perform the same upon the terms and conditions in the Original Mortgage set forth, including the following: 
 The
Trustee shall not be responsible in any manner whatsoever for or in respect of the validity or sufficiency of this Fifty-first Supplemental Indenture or for or in respect of the recitals contained herein, all of which recitals are made by the
Company solely. Each and every term and condition contained in Article XVI of the Original Mortgage shall apply to and form part of this Fifty-first Supplemental Indenture with the same force and effect as if the same were herein set forth in full,
with such omissions, variations and insertions, if any, as may be appropriate to make the same conform to the provisions of this Fifty-first Supplemental Indenture. 
 SECTION 3. Whenever in this Fifty-first Supplemental Indenture either of the parties hereto is named or referred to, this shall, subject to the provisions of Articles XV and XVI of the Original Mortgage
be deemed to include the successors and assigns of such party, and all the covenants and agreements in this Fifty-first Supplemental Indenture contained by or on behalf of the Company, or by or on behalf of the Trustee, or either of them, shall,
subject as aforesaid, bind and inure to the respective benefits of the respective successors and assigns of such parties, whether so expressed or not. 
 SECTION 4. Nothing in this Fifty-first Supplemental Indenture, expressed or implied, is intended, or shall be construed, to confer upon, or to give to, any person, firm or corporation, other than the
parties hereto and the holders of the bonds and coupons Outstanding under the Mortgage, any right, remedy or claim under or by reason of this Fifty-first Supplemental Indenture or any covenant, condition, stipulation, promise or agreement hereof,

  
 9 

 
and all the covenants, conditions, stipulations, promises and agreements in this Fifty-first Supplemental Indenture contained by or on behalf of the Company shall be for the sole and exclusive
benefit of the parties hereto, and of the holders of the bonds and of the coupons Outstanding under the Mortgage. 
 SECTION 5.
This Fifty-first Supplemental Indenture shall be executed in several counterparts, each of which shall be an original and all of which shall constitute but one and the same instrument. 

SECTION 6. The titles of the several Articles of this Fifty-first Supplemental Indenture shall not be deemed to be any part thereof.

  
  

  
 10 

 IN WITNESS WHEREOF, on the 11th day of February, 2011, AVISTA CORPORATION has caused its corporate
name to be hereunto affixed, and this instrument to be signed and sealed by its President or one of its Vice Presidents, and its corporate seal to be attested by its Corporate Secretary or one of its Assistant Corporate Secretaries for and in its
behalf, all in The City of Spokane, Washington, as of the day and year first above written; and on the 11th day of February, 2011, CITIBANK, N.A., has caused its corporate name to be hereunto affixed, and this instrument to be signed and sealed by its President or one of its Vice Presidents or one of its
Senior Trust Officers or one of its Trust Officers and its corporate seal to be attested by one of its Vice Presidents or one of its Trust Officers, all in The City of New York, New York, as of the day and year first above written. 

 

			
	AVISTA CORPORATION
		
	By:	 	 /s/ Jason R. Thackston

		 	Name: Jason R. Thackston
		 	Title: Vice President

  

	
	Attest:
	
	 /s/ Susan Y. Fleming

	 Name: Susan Y. Fleming
 Title:
Assistant Corporate Secretary

	
	 Executed, sealed and delivered
by AVISTA CORPORATION
in the presence of:

	
	 /s/ Ryan L. Krasselt

	 Name: Ryan L. Krasselt
 Title:
Treasury Financing Manager

	
	 /s/ Damien T. Lysiak

	 Name: Damien T. Lysiak
 Title:
Treasury Analyst

  
 11 

 
			
	CITIBANK, N.A., AS TRUSTEE
		
	By:	 	 /s/ Wafaa Orfy

		 	Name: Wafaa Orfy
		 	Title: Vice President

  

	
	Attest:
	
	 /s/ Louis Piscitelli

	Name: Louis Piscitelli
	Title: Vice President
	
	 Executed, sealed and delivered
by CITIBANK, N.A.,
as trustee, in the presence of:

	
	 /s/ John Hannon

	Name: John Hannon
	
	 /s/ Cirino Emanuele

	Name: Cirino Emanuele

  
 12 

			
	STATE OF WASHINGTON	  	)
		  	) ss.:
	COUNTY OF SPOKANE	  	)

 On the 11th day of February, 2011, before me personally appeared Jason R.
Thackston, to me known to be a Vice President of AVISTA CORPORATION, one of the corporations that executed the within and foregoing instrument, and acknowledged said instrument to be the free and voluntary act and deed of said Corporation for the
uses and purposes therein mentioned and on oath stated that he was authorized to execute said instrument and that the seal affixed is the corporate seal of said Corporation. 

On the 11th day of February, 2011, before me, a Notary Public in and for the State and County aforesaid, personally appeared Jason
R. Thackston, known to me to be a Vice President of AVISTA CORPORATION, one of the corporations that executed the within and foregoing instrument and acknowledged to me that such Corporation executed the same. 

IN WITNESS WHEREOF, I have hereunto set my hand and affixed my official seal the day and year first above written. 

 

	
	 /s/ Rae An Cornell

	Notary Public
	
	RAE AN CORNELL
	 Notary Public
 State Of Washington
 Commission Expires January 29, 2014

  
 13 

			
	STATE OF NEW YORK	  	)
		  	) ss.:
	COUNTY OF NEW YORK	  	)

 On the 9th day of February, 2011, before me personally appeared Wafaa Orfy, to
me known to be a Vice President of CITIBANK, N.A., one of the corporations that executed the within and foregoing instrument, and acknowledged said instrument to be the free and voluntary act and deed of said Corporation for the uses and purposes
therein mentioned and on oath stated that he was authorized to execute said instrument and that the seal affixed is the corporate seal of said Corporation. 
 On the 9th
day of February, 2011, before me, a Notary Public in and for the State and County aforesaid, personally appeared Wafaa Orfy, known to me to be an Vice President of CITIBANK, N.A., one of the corporations that executed the within and foregoing
instrument and acknowledged to me that such Corporation executed the same. 
 IN WITNESS WHEREOF, I have hereunto set my hand
and affixed my official seal the day and year first above written. 
  

	
	 /s/ Noreen Iris Santos

	Notary Public
	
	NOREEN IRIS SANTOS
	Notary Public, State Of New York
	Registration #01SA6228750
	Qualified in Nassau County
	Commission Expires Sept. 27, 2014

  
 14 

 EXHIBIT A 
 MORTGAGE, SUPPLEMENTAL INDENTURES 
 AND SERIES OF BONDS

  

													
	 MORTGAGE OR SUPPLEMENTAL
INDENTURE
	  	 DATED AS OF
	  	 SERIES
	  	PRINCIPAL
AMOUNT

ISSUED	 	  	 PRINCIPAL

AMOUNT
OUTSTANDING

	  	  	 NO.
	 	 DESIGNATION
	  	  
	 Original
	  	June 1, 1939	  	1	 	3 1/2% Series due 1964	  	$	22,000,000	  	  	None
						
	 First
	  	October 1, 1952	  	2	 	3 3/4% Series due 1982	  	 	30,000,000	  	  	None
						
	 Second
	  	May 1, 1953	  	3	 	3 7/8% Series due 1983	  	 	10,000,000	  	  	None
						
	 Third
	  	December 1, 1955	  		 	None	  				  	
						
	 Fourth
	  	March 15, 1957	  		 	None	  				  	
						
	 Fifth
	  	July 1, 1957	  	4	 	4 7/8% Series due 1987	  	 	30,000,000	  	  	None
						
	 Sixth
	  	January 1, 1958	  	5	 	4 1/8% Series due 1988	  	 	20,000,000	  	  	None
						
	 Seventh
	  	August 1, 1958	  	6	 	4 3/8% Series due 1988	  	 	15,000,000	  	  	None
						
	 Eighth
	  	January 1, 1959	  	7	 	4 3/4% Series due 1989	  	 	15,000,000	  	  	None
						
	 Ninth
	  	January 1, 1960	  	8	 	5 3/8% Series due 1990	  	 	10,000,000	  	  	None
						
	 Tenth
	  	April 1, 1964	  	9	 	4 5/8% Series due 1994	  	 	30,000,000	  	  	None
						
	 Eleventh
	  	March 1 ,1965	  	10	 	4 5/8% Series due 1995	  	 	10,000,000	  	  	None
						
	 Twelfth
	  	May 1, 1966	  		 	None	  				  	
						
	 Thirteenth
	  	August 1, 1966	  	11	 	6 % Series due 1996	  	 	20,000,000	  	  	None
						
	 Fourteenth
	  	April 1, 1970	  	12	 	9 1/4% Series due 2000	  	 	20,000,000	  	  	None
						
	 Fifteenth
	  	May 1, 1973	  	13	 	7 7/8% Series due 2003	  	 	20,000,000	  	  	None
						
	 Sixteenth
	  	February 1, 1975	  	14	 	9 3/8% Series due 2005	  	 	25,000,000	  	  	None
						
	 Seventeenth
	  	November 1, 1976	  	15	 	8 3/4% Series due 2006	  	 	30,000,000	  	  	None
						
	 Eighteenth
	  	June 1, 1980	  		 	None	  				  	
						
	 Nineteenth
	  	January 1, 1981	  	16	 	14 1/8% Series due 1991	  	 	40,000,000	  	  	None

  

  
 A-1

													
	 MORTGAGE OR SUPPLEMENTAL

INDENTURE
	  	 DATED AS OF
	  	 SERIES
	  	PRINCIPAL
AMOUNT

ISSUED	 	  	 PRINCIPAL

AMOUNT

OUTSTANDING

	  	  	NO.	  	 DESIGNATION
	  	  
	 Twentieth
	  	August 1, 1982	  	17	  	
15 3/4% Series due
 1990-1992
	  	 	60,000,000	  	  	None
						
	 Twenty-First
	  	September 1, 1983	  	18	  	
13 1/2% Series due
 2013
	  	 	60,000,000	  	  	None
						
	 Twenty-Second
	  	March 1, 1984	  	19	  	
13 1/4% Series due
 1994
	  	 	60,000,000	  	  	None
						
	 Twenty-Third
	  	December 1, 1986	  	20	  	9 1/4% Series due 2016	  	 	80,000,000	  	  	None
						
	 Twenty-Fourth
	  	January 1, 1988	  	21	  	
10 3/8% Series due
 2018
	  	 	50,000,000	  	  	None
						
	 Twenty-Fifth
	  	October 1, 1989	  	22  
 23
	  	 7 1/8% Series due 2013
 7 2/5% Series due 2016

 
	  	   
  
	66,700,000  
 17,000,000
	    
   
	  	 None
  

None

						
	 Twenty-Sixth
	  	April 1, 1993	  	24	  	 Secured Medium-Term
 Notes, Series A
 ($250,000,000

authorized)
	  	 	250,000,000	  	  	43,000,000
						
	 Twenty-Seventh
	  	January 1, 1994	  	25	  	 Secured Medium-Term
 Notes, Series B
 ($250,000,000

authorized)
	  	 	161,000,000	  	  	None
						
	 Twenty-Eighth
	  	September 1, 2001	  	26	  	 Collateral Series due
 2002
	  	 	220,000,000	  	  	None
						
	 Twenty-Ninth
	  	December 1, 2001	  	27	  	7.75% Series due 2007	  	 	150,000,000	  	  	None
						
	 Thirtieth
	  	May 1, 2002	  	28	  	 Collateral Series due
 2003
	  	 	225,000,000	  	  	None
						
	 Thirty-first
	  	May 1, 2003	  	29	  	 Collateral Series due
 2004
	  	 	245,000,000	  	  	None
						
	 Thirty-second
	  	September 1, 2003	  	30	  	6.125% Series due 2013	  	 	45,000,000	  	  	None
						
	 Thirty-third
	  	May 1, 2004	  	31	  	 Collateral Series due
 2005
	  	 	350,000,000	  	  	None
						
	 Thirty-fourth
	  	November 1, 2004	  	32	  	5.45% Series due 2019	  	 	90,000,000	  	  	90,000,000
						
	 Thirty-fifth
	  	December 1, 2004	  	33	  	Collateral Series 2004A	  	 	88,850,000	  	  	25,000,000

  
 A-2

													
	 MORTGAGE OR SUPPLEMENTAL

INDENTURE
	  	 DATED AS OF
	  	 SERIES
	  	PRINCIPAL
AMOUNT

ISSUED	 	  	PRINCIPAL
AMOUNT
OUTSTANDING
	  	  	NO.	  	 DESIGNATION
	  	  
	 Thirty-sixth
	  	December 1, 2004	  	34  
 35
	  	 Collateral Series 2004B
 Collateral Series 2004C
	  	   
  
	66,700,000  
 17,000,000
	    
   
	  	None  
 None

						
	 Thirty-seventh
	  	December 1, 2004	  	36	  	Collateral Series 2004D	  	 	350,000,000	  	  	None
						
	 Thirty-eighth
	  	May 1, 2005	  	37  
 38
	  	 Collateral Series 2005B
 Collateral Series 2005C
	  	   
  
	66,700,000  
 17,000,000
	    
   
	  	None  
 None

						
	 Thirty-ninth
	  	November 1, 2005	  	39	  	6.25% Series due 2035	  	   
  
	100,000,000  

50,000,000
	    
   
	  	100,000,000  

50,000,000

						
	 Fortieth
	  	April 1, 2006	  	40	  	 Collateral Series due
 2011
	  	 	320,000,000	  	  	320,000,0001
						
	 Forty-first
	  	December 1, 2006	  	41	  	5.70% Series due 2037	  	 	150,000,000	  	  	150,000,000
						
	 Forty-second
	  	April 1, 2008	  	42	  	5.95% Series due 2018	  	 	250,000,000	  	  	250,000,000
						
	 Forty-third
	  	November 1, 2008	  	43	  	Collateral Series 2008A	  	 	200,000,000	  	  	None
						
	 Forty-fourth
	  	December 1, 2008	  	44	  	7.25% Series due 2013	  	 	30,000,000	  	  	None
						
	 Forty-fifth
	  	December 1, 2008	  	45	  	Collateral Series 2008B	  	 	17,000,000	  	  	None
						
	 Forty-sixth
	  	September 1, 2009	  	46	  	5.125% Series due 2022	  	 	250,000,000	  	  	250,000,000
						
	 Forty-seventh
	  	September 1, 2009	  	47	  	Collateral Series 2009A	  	 	75,000,000	  	  	75,000,0001
						
	 Forty-eighth
	  	December 1, 2010	  	48
 49
	  	 Collateral Series 2010A
 Collateral Series 2010B
	  	 
  
	66,700,000
 17,000,000
	  
   
	  	66,700,000

17,000,000

						
	 Forty-ninth
	  	December 1, 2010	  	50
 51
	  	 3.89% Series due 2020
 5.55% Series due 2040
	  	 
  
	52,000,000
 35,000,000
	  
   
	  	52,000,000

35,000,000

						
	 Fiftieth
	  	December 1, 2010	  	52	  	1.68% Series due 2013	  	 	50,000,000	  	  	50,000,000

  

	1	 To be retired in connection with the delivery of $400,000,000 of First Mortgage Bonds, Collateral Series 2011A. 

  
 A-3

 EXHIBIT B 
 (Form of Bond) 
 This bond is non-transferable, except to a successor

 Administrative Agent under the Credit Agreement referred to herein. 

AVISTA CORPORATION 
 First Mortgage Bond, 
 Collateral Series 2011A 

			
	 REGISTERED
	 	REGISTERED
		
	 NO.         
	 	$400,000,000

 AVISTA
CORPORATION, a corporation of the State of Washington (hereinafter called the “Company”), for value received, hereby promises to pay to 
 , as Administrative Agent under the Credit Agreement hereinafter referred to or registered assigns on February 11 2015 (or such later date to which such Stated Maturity shall have been extended as
provided below) 
 DOLLARS 
 and to pay the registered owner hereof interest thereon from February 11, 2011 in arrears on March 31, June 30, September 30 and December 31 of each year, commencing
March 31, 2011 (each such date being hereinafter called an “Interest Payment Date”) and at Maturity (as hereinafter defined), at the rate of eight per centum (8%) per annum computed as provided in the Fifty-first Supplemental
Indenture hereinafter referred to, until the Company’s obligation with respect to the payment of such principal shall have been discharged. The principal of and premium, if any, and interest on this bond payable at Maturity shall be payable
upon presentation hereof at the office or agency of the Company in the Borough of Manhattan, The City of New York, in such coin or currency of the United States of America as at the time of payment is legal tender for public and private debts. The
interest on this bond (other than interest payable at Maturity) shall be paid directly to the registered owner hereof. Interest payable at Maturity shall be paid to the person to whom principal shall be paid. As used herein, the term
“Maturity” shall mean the date on which the principal of this bond becomes due and payable, whether at stated maturity, upon redemption or acceleration, or otherwise. 

This bond is one of an issue of bonds of the Company issuable in series and is one of a series known as its First Mortgage Bonds,
Collateral Series 2011A, all bonds of all such series being issued and issuable under and equally secured (except insofar as any sinking or other fund, established in accordance with the provisions of the Mortgage hereinafter mentioned, may afford
additional security for the bonds of any particular series) by a Mortgage and Deed of Trust, dated as of June 1, 1939 (the “Original Mortgage”), executed by the Company (formerly

  
 B-1

 
known as The Washington Water Power Company) to City Bank Farmers Trust Company and Ralph E. Morton, as Trustees (Citibank, N.A., successor Trustee to both said Trustees). The Original Mortgage
has been amended and supplemented by various supplemental indentures, including the Fifty-first Supplemental Indenture, dated as of February 1, 2011 (the “Fifty-first Supplemental Indenture”) and, as so amended and supplemented, is
herein called the “Mortgage.” Reference is made to the Mortgage for a description of the property mortgaged and pledged, the nature and extent of the security, the rights of the holders of the bonds and of the Trustee in respect thereof,
the duties and immunities of the Trustee and the terms and conditions upon which the bonds are and are to be secured and the circumstances under which additional bonds may be issued. If there shall be a conflict between the terms of this bond and
the provisions of the Mortgage, the provisions of the Mortgage shall control to the extent permitted by law. The holder of this bond, by its acceptance hereof, shall be deemed to have consented and agreed to all of the terms and provisions of the
Mortgage. 
 The Mortgage may be modified or altered by affirmative vote of the holders of at least 60% in principal amount of
the bonds outstanding under the Mortgage, considered as one class, or, if the rights of one or more, but less than all, series of bonds then outstanding are to be affected, then such modification or alteration may be effected with the affirmative
vote only of 60% in principal amount of the bonds outstanding of the series so to be affected, considered as one class, and, furthermore, for limited purposes, the Mortgage may be modified or altered without any consent or other action of holders of
any series of bonds. No modification or alteration shall, however, permit an extension of the Maturity of the principal of, or interest on, this bond or a reduction in such principal or the rate of interest hereon or any other modification in the
terms of payment of such principal or interest or the creation of any lien equal or prior to the lien of the Mortgage or deprive the holder of a lien on the mortgaged and pledged property without the consent of the holder hereof. 

The bonds of this series are not redeemable, in whole or in part, at the option of the Company. 

The bonds of this series have been issued and delivered to Union Bank, N.A., as Administrative Agent under the Credit Agreement (as such
terms are defined in the Fifty-first Supplemental Indenture) in order to provide the benefit of the lien of the Mortgage as security for the obligation of the Company under the Credit Agreement to pay the Obligations (as so defined), to the extent
and subject to the limitations set forth below. 
 Upon the earliest of (A) the occurrence of an Event of Default (as
defined in the Fifty-first Supplemental Indenture), and further upon the condition that, in accordance with the terms of the Credit Agreement, the Commitments (as so defined) shall have been or shall have terminated and any Loans (as so defined)
outstanding shall have been declared to be or shall have otherwise become due and payable immediately and the Administrative Agent shall have demanded that the Company provide cash collateral in the amount of the total LC Exposure (as so defined)
and the Administrative Agent shall have delivered to the Company a notice demanding redemption of the bonds of this series which notice states that it is being delivered pursuant to Article VII of the Credit Agreement, (B) the occurrence of an
Event of Default under clause (g) or (h) of Article VII of the Credit Agreement, and (C) the Stated Maturity (as defined below), then all bonds of this series shall be redeemed or paid immediately at the principal amount thereof plus
accrued interest to the date of redemption or payment. 

  
 B-2

 The obligation of the Company to pay the accrued interest on bonds of this series on any
Interest Payment Date prior to Maturity (a) shall be deemed to have been satisfied and discharged in full in the event that all amounts then due in respect of the Obligations shall have been paid or (b) shall be deemed to remain
unsatisfied in an amount equal to the aggregate amount then due in respect of the Obligations and remaining unpaid (not in excess, however, of the amount otherwise then due in respect of interest on the bonds of this series). 

The obligation of the Company to pay the principal of and accrued interest on bonds of this series at or after Maturity (x) shall be
deemed to have been satisfied and discharged in full in the event that all amounts then due in respect of the Obligations shall have been paid or (y) shall be deemed to remain unsatisfied in an amount equal to the aggregate amount then due in
respect of the Obligations and remaining unpaid (not in excess, however, of the amount otherwise then due in respect of principal of and accrued interest on the bonds of this series). 

As used herein, “Stated Maturity” means February 11, 2015 or such later date to which such date shall have been extended
as provided in the Fifty-first Supplemental Indenture. 
 Anything in this bond to the contrary notwithstanding, if, at the time
of the Maturity of the bonds of this series, the stated aggregate principal amount of such bonds then outstanding shall exceed the aggregate Commitments, the aggregate principal amount of such bonds shall be deemed to have been reduced by the amount
of such excess. 
 The principal hereof may be declared or may become due prior to the stated maturity date on the conditions,
in the manner and at the time set forth in the Mortgage, upon the occurrence of a Completed Default as in the Mortgage provided. 
 As provided in the Mortgage and subject to certain limitations therein set forth, this bond or any portion of the principal amount hereof will be deemed to have been paid if there has been irrevocably
deposited with the Trustee moneys or direct obligations of or obligations guaranteed by the United States of America, the principal of and interest on which when due, and without regard to any reinvestment thereof, will provide moneys which,
together with moneys so deposited, will be sufficient to pay when due the principal of and premium, if any, and interest on this bond when due. 
 The Mortgage contains terms, provisions and conditions relating to the consolidation or merger of the Company with or into, and the conveyance or other transfer, or lease, of assets to, another
corporation and to the assumption by such other corporation, in certain circumstances, of all of the obligations of the Company under the Mortgage and on the bonds secured thereby. 

This bond is non-transferable except as required to effect transfer to any successor administrative agent under the Credit Agreement, any
such transfer to be made at the office or agency of the Company in the Borough of Manhattan, The City of New York, upon surrender and cancellation of this bond, together with a written instrument of transfer whenever required by the Company duly
executed by the registered owner or by its duly authorized attorney, and, 

  
 B-3

 
thereupon, a new fully registered bond of the same series for a like principal amount will be issued to the transferee in exchange herefor as provided in the Mortgage. The Company and the Trustee
may deem and treat the person in whose name this bond is registered as the absolute owner hereof for the purpose of receiving payment and for all other purposes. 
 In the manner prescribed in the Mortgage, any bonds of this series, upon surrender thereof for cancellation at the office or agency of the Company in the Borough of Manhattan, The City of New York, are
exchangeable for a like aggregate principal amount of bonds of the same series of other authorized denominations. 
 No recourse
shall be had for the payment of the principal of or interest on this bond against any incorporator or any past, present or future subscriber to the capital stock, stockholder, officer or director of the Company or of any predecessor or successor
corporation, as such, either directly or through the Company or any predecessor or successor corporation, under any rule of law, statute or constitution or by the enforcement of any assessment or otherwise, all such liability of incorporators,
subscribers, stockholders, officers and directors being released by the holder or owner hereof by the acceptance of this bond and being likewise waived and released by the terms of the Mortgage. 

This bond shall not become obligatory until Citibank, N.A., the Trustee under the Mortgage, or its successor thereunder, shall have
signed the form of certificate endorsed hereon. 
 IN WITNESS WHEREOF, AVISTA CORPORATION has caused this bond to be
signed in its corporate name by its President or one of its Vice Presidents by his signature or a facsimile thereof, and its corporate seal to be impressed or imprinted hereon and attested by its Corporate Secretary or one of its Assistant Corporate
Secretaries by his signature or a facsimile thereof. 
  

							
	Dated:	 		 		 	
			
		 		 	AVISTA CORPORATION
				
		 		 	By:	 	  

		 		 	Name	 	
		 		 	Title:	 	

  

							
	 ATTEST:
	 	  
	  		  	

  

  
 B-4

 TRUSTEE’S CERTIFICATE 

This bond is one of the bonds, of the series herein designated, described or provided for in the within-mentioned Mortgage. 

 

			
	CITIBANK, N.A.
	Trustee
		
	By:	 	  

		 	Authorized Signatory

  
 B-5

 ASSIGNMENT FORM 

FOR VALUE RECEIVED the undersigned hereby sells, assigns and transfers unto 
                                  
                                         
                                         
          
 [please insert social security or other identifying number of
assignee] 

                         
                                         
                                         
                  
 [please print or
typewrite name and address of assignee] 

                         
                                         
                                         
                  
 the within bond of AVISTA
CORPORATION and does hereby irrevocably constitute and appoint                     
                    , Attorney, to transfer said bond on the books of the within-mentioned Company, will full power of substitution in the
premises. 
 Dated:
                     
  

			
		 	  

		 	[signature of assignor]

  

			
		 	Notice: The signature to this assignment must correspond with the name as written upon the face of the bond in every particular without alteration or enlargement or any change
whatsoever.

  
 B-6

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00184-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00184-of-00352.parquet"}]]